Vismodegib (GDC-0449)

Vismodegib (GDC-0449) targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. This compound prevents multiple ATP-binding cassette (ABC) transporters and also blocks ABCG2, Pgp, and MRP1—important ABC transporters associated with MDR. It is a potent inhibitor of ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In ABCG2-overexpressing HEK293 cells, it increases retention of the fluorescent ABCG2 substrate BODIPY and resensitizes these cells. In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, it increases the retention of calcein-AM and resensitizes them. It also resensitizes human non-small cell lung carcinoma cells NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to SN-38. The IC50 values for prevention of ABCG2 and Pgp are about 1.4 μM and 3.0 μM, respectively. ^[2] Additionally, it alters intracellular Ca²⁺ homeostasis and inhibits cell growth in resistant lung cancer cells. ^[3]

Vismodegib (GDC-0449) has been used to treat medulloblastoma in animal models. ^[2] It prevents the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation. Oral dosing of this compound causes tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent colorectal cancer models, D5123, and 1040830. Analysis of Hh pathway activity and PK/PD modeling reveals that it inhibits Gli1 with a similar IC50 in both the medulloblastoma and D5123 models (0.165 μM and 0.267 μM, respectively). Pathway modulation is linked to efficacy using an integrated PK/PD model revealing a steep relationship where > 50% of the activity of GDC-0449 is associated with >80% repression of the Hh pathway. ^[4]

• Cell lines

  MDCKII cells

• Concentrations

  20 μM

• Incubation Time

  2 hours

• Method

  MDCKII cells are seeded into 24-well plates at a density of 3 × 10⁵ cells per well and are allowed to attach. Medium is then changed to that containing different drugs (50 μM VP, or 20 μM Vismodegib (GDC-0449) in DMSO or DMSO alone as control, and nonfluorescent calcein-AM is added to a final concentration of 1.0 μM and incubated at 37 °C for 2 hours. It is then used in subsequent steps. Cells are washed twice with Ca²⁺, Mg²⁺-containing Hank's balanced salt solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS buffer for 1 hour at room temperature or overnight at 4 °C. The lysate is then transferred into 96-well plates, and the fluorescence signal caused by the cell-derived calcein is quantified spectrophotometrically with a SpectraMax M5 Multi-Detection Readerusing an excitation wavelength of 495 nm and an emission wavelength of 515 nm. All manipulations are performed in the dark. All readings are expressed as mean ?SEM normalized to the control.

• Animal Models

  Ptch(+/-) allograft model, D5123 and 1040830

• Dosages

  ~ 100 mg/kg

• Administration

  Orally